secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-067012
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q4 net loss $183M; MYQORZO launch underway; cash $1.22B; guides 2026 spend $830-870M
--------------------------------------------------------------------------------

- Net loss Q4 2025 $183M ($1.50/sh) vs $150M ($1.26) Q4 2024; full year loss $785M ($6.54) vs $589.5M ($5.26).
- Revenue Q4 $17.8M (up 5% YoY); full year $88.0M (up 376% YoY) from Bayer tech transfer $52.4M and Sanofi milestones $15.0M.
- Cash $1.22B at Dec 31 2025; Q4 cash burn ~$134M excluding $100M loan draw from Royalty Pharma.
- MYQORZO (aficamten) approved for oHCM in US (Dec 2025), China, EU; US launch underway Jan 2026; ACACIA-HCM topline expected Q2 2026.
- FY 2026 GAAP combined R&D+SG&A guidance $830-870M; non-cash stock comp $130-120M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/0001193125-26-067012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-067012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer